401-456-2000

For Caregivers

In This Section

Immunotherapy Protocols

HITM-SURE: “A PHASE Ib TRIAL OF CAR-T HEPATIC ARTERY INFUSIONS DELIVERED WITH THE SUREFIRE INFUSION SYSTEM FOR CEA EXPRESSING LIVER METASTASES”
Principal Investigator: Dr. Steven C. Katz, MD, FACS

Eligibility Criteria: 

  • Tumor must be CEA-expressing demonstrated by elevated CEA level (CEA >10)
  • Liver metastases must be documented
  • Failed at least one line of conventional chemotherapy
  • Good performance status

Contact Information

Ashley Moody, BSN, RN 
Immunotherapy Nurse Coordinator
RWMC Protocol Office
Phone: 401-456-2268
alarkin@chartercare.org